TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8694155

Group type: EXPERIMENTAL
Intervention: mivacurium 0.2 mg.kg‐1
Number of subjects: 121

Group type: COMPARATOR
Intervention: anaesthetic drugs alone
Number of subjects: 121
Study: 1459169

Group type: EXPERIMENTAL
Intervention: MaxEPA (3 g n-3 fatty acids)
Number of subjects: 14
Study: 3902241

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 44
Study: 29663065

Group type: EXPERIMENTAL
Intervention: Multimodal individual activation performed by relatives 6 days per week, cognitive stimulation once a week by an external person, over a 6-month intervention period.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study: 30577611

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Soy protein isolate (SPI)
Number of subjects: 56
Study: 27669178

Group type: EXPERIMENTAL
Intervention: Individually tailored physical activity intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: Wellness control group
Number of subjects: 266
Study: 24994841

Group type: EXPERIMENTAL
Intervention: CCM excision
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 134
Study: 23270253

Group type: EXPERIMENTAL
Intervention: Transitory Stimulation Interval Exercise (TSIE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous Moderate Exercise (CME)
Number of subjects: 30
Study: 20424555

Group type: EXPERIMENTAL
Intervention: L-arginine (12 g daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 19078834

Group type: EXPERIMENTAL
Intervention: Prehospital abciximab treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Periprocedural abciximab treatment
Number of subjects: 101
Study: 15950849

Group type: EXPERIMENTAL
Intervention: Single injection of 15 mL of 0.5% bupivacaine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Multiple injections (3 injections) of 15 mL of 0.5% bupivacaine (5 mL each at C2, C3, C4)
Number of subjects: 24
Study: 12027926

Group type: EXPERIMENTAL
Intervention: Patient Participation Programme (PP)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard Consultation (SC)
Number of subjects: 165
Study: 10710970

Group type: EXPERIMENTAL
Intervention: Monetary incentive ($1)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No monetary incentive (Control)
Number of subjects: 600
Study: 7669649

Group type: EXPERIMENTAL
Intervention: 40 mg SDZ IMM 125 daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 100 mg SDZ IMM 125 daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 200 mg SDZ IMM 125 daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 400 mg SDZ IMM 125 daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 2257964

Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine taken once nightly
Number of subjects: 50

Group type: COMPARATOR
Intervention: 400 mg cimetidine taken twice daily
Number of subjects: 50
Study: 7003687

Group type: EXPERIMENTAL
Intervention: Lunerin (oral decongestant: brompheniramine maleate and phenylpropanolamine hydrochloride)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study: 31937137

Group type: EXPERIMENTAL
Intervention: Revascularization + best medical therapy + structured exercise therapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Best medical therapy + structured exercise therapy (nonrevascularization group)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Revascularization strategy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Noninvasive treatment approach
Number of subjects: 158
Study: 30829901

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 3‐min intervals at 40% and 80% of V˙O2max, n = 18, for 30 min·d, 5 d·wk for 6 wk
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT) - sustained 60% of V˙O2max, n = 18, for 30 min·d, 5 d·wk for 6 wk
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n = 18) - no exercise intervention
Number of subjects: 54
Study: 28746558

Group type: EXPERIMENTAL
Intervention: Prayer intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no prayer)
Number of subjects: 95
Study: 26673225

Group type: EXPERIMENTAL
Intervention: Relaxation‐Response‐based Mental Health Promotion (RR‐MHP) program (Open and Calm)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 72
Study: 23566529

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT)
Number of subjects: 63
Study: 22013800

Group type: EXPERIMENTAL
Intervention: Xiaozhang Recipe (XR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Fuzheng Huayu Capsule
Number of subjects: 84
Study: 19222595

Group type: EXPERIMENTAL
Intervention: Carisbamate 100 mg/day
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Carisbamate 300 mg/day
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Carisbamate 600 mg/day
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 16505397

Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadolinium chelate (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.4 mmol/kg gadolinium chelate (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 60
Study: 14697926

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard regimen (N-BG)
Number of subjects: 43
Study: 11104316

Group type: EXPERIMENTAL
Intervention: Beh (intensive, multi-faceted behavior therapy program)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: MedMgt (carefully titrated and monitored medication management strategy)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Comb (well-integrated combination of behavior therapy and medication management)
Number of subjects: 579

Group type: COMPARATOR
Intervention: CC (community comparison group)
Number of subjects: 579
Study: 9158270

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8082361

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 20 mg by mouth, three times a day for 7 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ethanol (1 ml/kg body weight, 50 percent)
Number of subjects: 14
Study: 2671121

Group type: EXPERIMENTAL
Intervention: Propranolol (doses reducing resting heart rate by 25%)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (vitamin K)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Propranolol (in subset without ascites)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (in subset without ascites)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Propranolol (in ascites-free period)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (in ascites-free period)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Propranolol (in patients with ascites)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (in patients with ascites)
Number of subjects: 174
Study: 919994

Group type: EXPERIMENTAL
Intervention: Mechanical preparation with antibiotics (lincomycline, neomycine, polymyxine, kanamycine, bacitracine, nystatine)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Mechanical preparation alone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Postoperative use of antibiotics for local or general infection
Number of subjects: 46
Study: 30649154

Group type: EXPERIMENTAL
Intervention: Running cuticular closure with 2-mm spacing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Running cuticular closure with 5-mm spacing
Number of subjects: 50
Study: 27834120

Group type: EXPERIMENTAL
Intervention: CTG + LLLT (test group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CTG (control group)
Number of subjects: 40
Study: 25666221

Group type: EXPERIMENTAL
Intervention: Mailed DESI in DVD format
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Shared medical appointment (SMA) to view the DESI
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Both mailed DESI and SMA
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2550
Study: 24975892

Group type: EXPERIMENTAL
Intervention: Bixalomer 1.5 g/day
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bixalomer 3.0 g/day
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bixalomer 4.5 g/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (HCl)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 22559260

Group type: EXPERIMENTAL
Intervention: Bare-metal stent implantation after pre-dilation with a drug-eluting balloon (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bare-metal stent implantation followed by post-dilation with a drug-eluting balloon (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bare-metal stent implantation alone (n=10)
Number of subjects: 30
Study: 19528367

Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 20 mg dapagliflozin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 17333949

Group type: EXPERIMENTAL
Intervention: Guided self-help for depression
Number of subjects: 24
Study: 15287853

Group type: EXPERIMENTAL
Intervention: lamivudine‐interferon (IFN)‐alpha combination therapy
Number of subjects: 16
Study: 11246937

Group type: EXPERIMENTAL
Intervention: Functional Pad A (low, uniform static magnetic field of negative polarity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional Pad B (low static magnetic field that varied spatially and in polarity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham groups (inactive magnets, identical in appearance and texture to functional pads)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care group (continued established treatment regimens)
Number of subjects: 0
Study: 9169288

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 10
Study: 1583328

Group type: COMPARATOR
Intervention: IL-1 production in response to leishmania antigens, heat-killed Listeria organisms, and lipopolysaccharide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IL-1 production post-therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: TNF production in response to leishmania antigens
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Serum TNF levels
Number of subjects: 16
Study: 3515060

Group type: EXPERIMENTAL
Intervention: Sharing medical records (experimental group)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (no sharing of medical records)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Less-educated patients (experimental group)
Number of subjects: 203
Study: 31946867

Group type: COMPARATOR
Intervention: Placebo group (sham stimulation during Instances Task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No stimulation group
Number of subjects: 0
Study: 30274112

Group type: EXPERIMENTAL
Intervention: Cysteine-linked antibacterial surface coating on nasal prongs
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-coated nasal prongs
Number of subjects: 48
Study: 27203302

Group type: EXPERIMENTAL
Intervention: G1‐PLUS™/G2‐PLUS™ sequential medium (Vitrolife)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GV BLAST™ sole medium (Ingamed)
Number of subjects: 60
Study: 24480867

Group type: COMPARATOR
Intervention: Normotensive Hispanic women at baseline
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Prehypertensive participants at baseline
Number of subjects: 4680

Group type: COMPARATOR
Intervention: Hypertensive participants compared to normotensive
Number of subjects: 4680
Study: 22886839

Group type: EXPERIMENTAL
Intervention: Warm humidified CO₂ (37°C, 100% relative humidity, 10 L/min)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (standard warming measures)
Number of subjects: 83
Study: 19922752

Group type: EXPERIMENTAL
Intervention: Hungry condition
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Overweight/obese group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Normal-weight group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Visual probe task
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Eye-tracking data
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: P300 amplitude
Number of subjects: 66
Study: 17358101

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20mg on-demand treatment
Number of subjects: 199

Group type: COMPARATOR
Intervention: Esomeprazole 20mg on-demand treatment
Number of subjects: 199
Study: 16326371

Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Diphenhydramine (40 mg)
Number of subjects: 42
Study: 11940697

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9468416

Group type: EXPERIMENTAL
Intervention: 11.5F polyethylene stent to be exchanged in case of dysfunction (group 1, n = 33)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 11.5F stent to be exchanged every 3 months (group 2, n = 34)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Self‐expanding metallic Wallstent (group 3, n = 34)
Number of subjects: 101
Study: 8552685

Group type: EXPERIMENTAL
Intervention: Formal asthma education programme delivered by an asthma nurse specialist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard information and education given to patients in a respiratory clinic
Number of subjects: 0
Study: 2137435

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.040 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.200 mg
Number of subjects: 10
Study: 6988949

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of tinidazole 2 g and doxycycline 200 mg (n = 70)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 265

Group type: COMPARATOR
Intervention: Tinidazole alone
Number of subjects: 265

Group type: COMPARATOR
Intervention: Two different combinations of the two antimicrobials
Number of subjects: 265
Study: 30463637

Group type: EXPERIMENTAL
Intervention: B'More Healthy Communities for Kids (BHCK) intervention
Number of subjects: 516
Study: 28114182

Group type: EXPERIMENTAL
Intervention: Multifaceted guideline implementation strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual implementation strategy
Number of subjects: 0
Study: 25616223

Group type: EXPERIMENTAL
Intervention: Coarse CAP (2.5‐10 μm; mean, 213 μg/m3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fine CAP (0.15‐2.5 μm; mean, 238 μg/m3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrafine CAP (< 0.3 μm; mean, 136 μg/m3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Filtered ambient and/or medical air
Number of subjects: 50
Study: 23356556

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Empagliflozin 100 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Empagliflozin (all doses combined)
Number of subjects: 78
Study: 21221770

Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg every 3 months
Number of subjects: 170

Group type: COMPARATOR
Intervention: Goserelin 3.6 mg every month
Number of subjects: 170
Study: 19114225

Group type: EXPERIMENTAL
Intervention: Traditional Bone Setting (TBS)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional Physical Therapy (PhT)
Number of subjects: 131
Study: 16452640

Group type: EXPERIMENTAL
Intervention: Phase concentration in the alpha frequency range
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing alpha activity prior to stimulus onset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evoked alpha oscillation in the ERP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lack of power increase during phase concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease in amplitude variance during early evoked components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Same cortical sources for induced prestimulus power and evoked poststimulus power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation approach to test the additivity of the evoked response
Number of subjects: 0
Study: 15064618

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 74

Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 74
Study: 11236773

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa activated (24 microg/kg/hour for 96 hours)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa activated
Number of subjects: 1690
Study: 9778009

Group type: EXPERIMENTAL
Intervention: 25 microg intrathecal neostigmine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 50 microg intrathecal neostigmine
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 75 microg intrathecal neostigmine
Number of subjects: 92

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 92
Study: 7923204

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg twice daily)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg twice daily)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 3289523

Group type: EXPERIMENTAL
Intervention: Alprazolam (mean dose, 4.2 mg/d)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diazepam (mean dose, 40.4 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 31425468

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK) at 2 μg·kg·min
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 59
Study: 28936678

Group type: EXPERIMENTAL
Intervention: Biomarker-based strategy (using (1,3)-β-D-glucan, mannan, and anti-mannan serum assays)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine care strategy (based on international guidelines recommending 14 days of treatment)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Biomarker-based strategy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine care strategy
Number of subjects: 110
Study: 25527447

Group type: EXPERIMENTAL
Intervention: FAST (rapid identification and antibiotic susceptibility testing using PCR)
Number of subjects: 250

Group type: COMPARATOR
Intervention: SOC (standard of care testing using the BD Phoenix system)
Number of subjects: 250
Study: 24048857

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg d-amphetamine orally
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21137035

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-flux hemodialysis treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control sets (post-dialytic samples from patients and samples from healthy controls)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-flux and low-flux hemodialysis treatments
Number of subjects: 16
Study: 19036450

Group type: EXPERIMENTAL
Intervention: Traditional services plus the services of a recovery coach (experimental group)
Number of subjects: 931

Group type: COMPARATOR
Intervention: Traditional services (control group)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Recovery coaches (experimental group)
Number of subjects: 931
Study: 16877894

Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 64
Study: 14692708

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU daily for 10 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 20
Study: 10824629

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of rTFPI (0.2 mg/kg/h) with intravenous sorbitol (50 mg/min) for 4 hours during exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of rTFPI (0.2 mg/kg/h) with intravenous sorbitol (50 mg/min) for 4 hours in supine position
Number of subjects: 8
Study: 8641622

Group type: EXPERIMENTAL
Intervention: ip mitoxantrone 10 mg/m2 every 2 weeks X 9
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: ip floxuridine (FUDR) 3 g (total dose)/ day X 3 days every 3 weeks X 6 cycles
Number of subjects: 67
Study: 1735812

Group type: EXPERIMENTAL
Intervention: PRP-CRM (polyribosylribitol phosphate conjugated with mutant diphtheria protein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-T (polyribosylribitol phosphate conjugated with tetanus toxoid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-OMP (polyribosylribitol phosphate conjugated with outer-membrane protein of Neisseria meningitidis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRP-D (polyribosylribitol phosphate conjugated with diphtheria toxoid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional diphtheria-tetanus-pertussis vaccine
Number of subjects: 0
Study: 6405430

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Promazine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30445177

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) combined with meibomian gland expression (MGX)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Meibomian gland expression (MGX) alone
Number of subjects: 45
Study: 29453383

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) + steroids
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham hyperbaric air + steroids
Number of subjects: 18
Study: 26890171

Group type: EXPERIMENTAL
Intervention: Weight Watchers weight‐management program (n=112)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Your Game Plan to Prevent Type 2 Diabetes (Control)
Number of subjects: 225